Mylan is a global healthcare company focused on making high quality medicines available to everyone who needs them.  Our broad and diverse portfolio of more than 7,500 marketed products is available to customers of all types including retail and pharmacy establishments, wholesalers, governments, institutions and physicians.

A History of Doing What’s Right

We began in 1961 as a company dedicated to helping people in small West Virginia towns and rural communities gain access to affordable medicine. Today, we remain dedicated to the same mission, but we do it for the world.

Looking to the Future

  1. 0

    Maintaining Quality in Everything We Do

    Because patients’ health and well-being are at stake, ensuring quality is essential for the pharmaceutical industry. That’s why, at Mylan, we view quality as being everyone’s responsibility.

    For us, quality begins with product development, as we work to ensure an acceptable safety and efficacy profile for every drug we hope to market, and it extends through every step of the production process, from making or sourcing raw materials to producing finished dosage forms.

    Externally we work with health authorities to help develop standards that reflect the requirements needed to develop and manufacture products. We then work hard to ensure that our sites, and those of third parties we rely on, comply with them.

    Our manufacturing facilities are routinely inspected by various health authorities around the world. In 2017, 128 inspections were performed across our facilities and affiliates.

    Mylan has global systems and processes in place to provide our people with the foundation and tools needed to maintain an effective quality management system.

    Our training programs, for instance, are designed to make sure employees are qualified by experience and education to perform their jobs in accordance with GMP. All employees responsible for GMP activities are required to take refresher training periodically.

    Our Quality Council program provides management with clear, quantitative data, including that of key performance indicators. It also tracks and analyzes quality trends, reviews inspection results and identifies potential areas for employee training.

    mylan quality values

  2. 0

    Increasing Generic Utilization

    We’re actively educating governments around the world about the role generic medicines play in affordable healthcare and access to medicine.
  3. 0

    Biosimilars: Advancing our Commitment

    Mylan has a combined portfolio of 20 biosimilar and insulin analog products in development, which is one of the industry’s largest and most diverse portfolios. Biosimilars play an important role in Mylan’s commitment to setting new standards in healthcare by offering quality alternatives to more costly therapeutic options and increasing access to treatment for patients.

    Biosimilars are products deemed highly similar to an already FDA-approved product known as a biological reference product and have no clinically meaningful differences in terms of safety and effectiveness from the reference product. These highly complex and often expensive therapies are used in diseases like cancer, multiple sclerosis, rheumatoid arthritis and diabetes. Biosimilar development uses the latest state-of-the-art analytical and biotechnology methods.

  • Our Values

    What sets us apart? Innovation, Integrity, Reliability, Service and Teamwork. Living our values is how we can work to provide 7 billion people access to high quality medicine.
    Discover how our values define us
  • Mylan Voices

    • Robert J Coury
      "We have one global quality standard because we know where our priorities are. It all starts and ends with you."
    • Heather Bresch
      Chief Executive Officer
      "Our mission is to provide 7 billion people access to high quality medicine.
      We are determined to put the care back in healthcare."
    • Rajiv Mallik
      "Setting new standards in healthcare is a promise that Mylan keeps every day."
  • Global Manufacturing

    Mylan has a global network of 47 operations facilities

    • Oral solid does manufacturing capacity: >75B doses
    • Injectables manufacturing capacity: >500M units
    • Complex products manufacturing capacity: 1.3B units
    • API capacity: >4,800KL


Meet our passionate global leaders.

Corporate Governance

Find governance documents, proxy information and policy statements.
  • Questions?

    Get more information on our products, services and Mylan Global Center locations.

    Contact us

  • Business Opportunities

    Do you have an opportunity or a collaboration idea?

    Partner with us